{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-25-000100","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.395593+00:00","generated_at":"2026-05-17T12:48:30.450000+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MacroGenics Q2 2025 net loss $36.3M; new CEO Eric Risser outlines strategic priorities","bullets":["Cash, equivalents and marketables $176.5M as of June 30, 2025; cash runway through first half 2027.","Total revenue $22.2M ($15.4M contract manufacturing, $6.9M collaboration vs. $10.8M year ago).","Net loss improved to $36.3M ($0.57/share) from $55.7M ($0.89/share) in Q2 2024.","Eric Risser named President and CEO, succeeding Scott Koenig who stepped down after 24 years.","Received $70M upfront from Sagard Healthcare for ZYNYZ royalty purchase agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-25-000100","json":"https://secwatch.observer/filing/0001125345-25-000100.json","markdown":"https://secwatch.observer/filing/0001125345-25-000100.md","text":"https://secwatch.observer/filing/0001125345-25-000100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534525000100/0001125345-25-000100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534525000100/mgnx-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:48:30.450000+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}